Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $9.50.

Several equities analysts have issued reports on the company. Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Sunday. Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. HC Wainwright lowered their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Finally, Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st.

Sana Biotechnology Trading Down 9.5%

NASDAQ SANA opened at $2.68 on Friday. The business’s 50 day moving average is $3.23 and its two-hundred day moving average is $3.81. Sana Biotechnology has a 12-month low of $2.41 and a 12-month high of $6.55. The stock has a market capitalization of $745.82 million, a price-to-earnings ratio of -2.88 and a beta of 2.14.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. Equities analysts forecast that Sana Biotechnology will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Sana Biotechnology by 19.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the period. State Street Corp grew its holdings in shares of Sana Biotechnology by 20.6% in the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after acquiring an additional 1,374,300 shares during the period. Geode Capital Management LLC grew its holdings in shares of Sana Biotechnology by 20.3% in the 4th quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock worth $16,763,000 after acquiring an additional 694,606 shares during the period. Integral Health Asset Management LLC grew its holdings in shares of Sana Biotechnology by 50.0% in the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock worth $12,210,000 after acquiring an additional 1,000,000 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of Sana Biotechnology by 148.4% in the 1st quarter. Bank of America Corp DE now owns 2,946,861 shares of the company’s stock worth $8,487,000 after acquiring an additional 1,760,610 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.